Aligos Therapeutics Inc (ALGS)
$6.14
$0.28
(4.78%)
As on 01-Sep-2026 16:00EDT
Market cap
$43 Mln
Revenue (TTM)
$32 Mln
P/E Ratio
--
P/B Ratio
1.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.6
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-7.3
-
Face value
--
-
Shares outstanding
5,444,558
6 Years Aggregate
CFO
$-401.13 Mln
EBITDA
$-461.43 Mln
Net Profit
$-486.80 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Aligos Therapeutics Inc (ALGS)
| -34.1 | 45.2 | 7.7 | -41.8 | -34.2 | -57.2 | -- |
|
BSE Sensex
| -9.1 | -1.5 | 2.9 | -3.6 | 5.9 | 6.0 | 10.5 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
|---|---|---|---|---|---|
|
Aligos Therapeutics Inc (ALGS)
| -76.6 | 138.3 | -30.3 | -92.0 | -57.1 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Aligos Therapeutics Inc (ALGS)
|
6.1 | 43.2 | 31.5 | -76.0 | -230.8 | -177.8 | -- | 1.4 |
| 82.7 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 71.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 56.9 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 107.7 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 363.8 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 538.7 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 583.2 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 | |
| 353.4 | 9,625.4 | 0.0 | -339.1 | -- | -30.6 | -- | 7.6 | |
| 146.5 | 9,339.4 | 282.0 | 82.9 | -28.6 | 11.4 | 140.1 | 11.5 |
Shareholding Pattern
View DetailsAbout Aligos Therapeutics Inc (ALGS)
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that... is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California. Read more
-
CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
-
CEO, President & Chairman of the Board
Dr. Lawrence M. Blatt MBA, Ph.D.
-
Headquarters
South San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Aligos Therapeutics Inc (ALGS)
What is the current share price of Aligos Therapeutics Inc (ALGS) Today?
The share price of Aligos Therapeutics Inc (ALGS) is $6.14 (NASDAQ) as of 01-Sep-2026 16:00 EDT. Aligos Therapeutics Inc (ALGS) has given a return of -34.17% in the last 3 years.
What is the current PB & PE ratio of Aligos Therapeutics Inc (ALGS)?
Since, TTM earnings of Aligos Therapeutics Inc (ALGS) is negative, P/E ratio is not available.
The P/B ratio of Aligos Therapeutics Inc (ALGS) is 1.39 times as on 28-Aug-2026, a 73 discount to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-4.00 |
1.81 |
2024 |
-1.91 |
-8.64 |
2023 |
-0.10 |
0.09 |
2022 |
-0.42 |
0.39 |
2021 |
-3.92 |
2.72 |
What is the 52 Week High and Low of Aligos Therapeutics Inc (ALGS)?
The 52-week high and low of Aligos Therapeutics Inc (ALGS) are Rs 13.69 and Rs 3.98 as of 02-Sep-2026.
What is the market cap of Aligos Therapeutics Inc (ALGS)?
Aligos Therapeutics Inc (ALGS) has a market capitalisation of $ 43 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Aligos Therapeutics Inc (ALGS)?
Before investing in Aligos Therapeutics Inc (ALGS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.